InCarda Therapeutics Appoints Dr. Myles Greenberg as New CEO
Portfolio - People | Dec 10, 2024 | HealthCap Venture Capital
InCarda Therapeutics has appointed Dr. Myles Greenberg as its new CEO as the company continues to advance its clinical development of an orally inhaled treatment for atrial fibrillation (AF). This novel formulation of flecainide, which aims to restore sinus rhythm rapidly and avoid common complications associated with AF, addresses a significant health concern affecting millions in the U.S. InCarda's mission is to develop home-use therapies, thus improving patients' quality of life. Dr. Greenberg brings nearly 25 years of experience in the life sciences sector, having a background in both clinical practice and business leadership, and aims to build InCarda into a leader in cardiac care solutions. The appointment sees Dr. Greenberg succeeding interim CEO Carlos Schuler, PhD, who will transition into the role of CTO. InCarda is supported by notable healthcare investors Deerfield Management and HealthCap.
Sectors
- Biopharmaceuticals
- Healthcare
- Venture Capital
Geography
- United States – The discussions around atrial fibrillation pertain to the U.S. healthcare system, and InCarda Therapeutics is based in Newark, California.
Industry
- Biopharmaceuticals – InCarda Therapeutics is involved in developing novel biopharmaceutical therapies for cardiac arrhythmias, particularly focused on creating treatments for atrial fibrillation.
- Healthcare – The article discusses treatments for cardiac arrhythmias, a significant healthcare concern, and the role of new healthcare technologies.
- Venture Capital – InCarda Therapeutics is backed by healthcare venture capital firms, indicating the industry's involvement in funding and supporting biopharmaceutical innovations.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| InCarda Therapeutics | Target Company | Company | A clinical-stage biopharmaceutical company focused on developing novel therapies for cardiac arrhythmias. |
| Dr. Myles Greenberg | New CEO | People | Appointed as the new president and CEO of InCarda Therapeutics with extensive experience in life sciences and healthcare technology. |
| Carlos Schuler, PhD | Interim CEO; New CTO | People | The co-founder of InCarda Therapeutics who will transition from interim CEO to CTO. |
| HealthCap | Investor | Company | A leading institutional healthcare investor backing InCarda Therapeutics. |
| Deerfield Management | Investor | Company | An institutional healthcare investor supporting InCarda Therapeutics. |
| Dan Welch | Executive Chairman | People | The executive chairman of InCarda Therapeutics, providing support and guidance to the company. |